ATE434035T1 - Lebender influenza impfstoff und verfahren zu seiner herstellung - Google Patents

Lebender influenza impfstoff und verfahren zu seiner herstellung

Info

Publication number
ATE434035T1
ATE434035T1 AT01985267T AT01985267T ATE434035T1 AT E434035 T1 ATE434035 T1 AT E434035T1 AT 01985267 T AT01985267 T AT 01985267T AT 01985267 T AT01985267 T AT 01985267T AT E434035 T1 ATE434035 T1 AT E434035T1
Authority
AT
Austria
Prior art keywords
cell culture
production
viruses
virus
influenza vaccine
Prior art date
Application number
AT01985267T
Other languages
English (en)
Inventor
Hermann Katinger
Andre Egorov
Boris Ferko
Julia Romanova
Dietmar Katinger
Original Assignee
Polymun Scient Immunbio Forsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polymun Scient Immunbio Forsch filed Critical Polymun Scient Immunbio Forsch
Application granted granted Critical
Publication of ATE434035T1 publication Critical patent/ATE434035T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01985267T 2000-09-25 2001-09-25 Lebender influenza impfstoff und verfahren zu seiner herstellung ATE434035T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00120896 2000-09-25
PCT/EP2001/011087 WO2002024876A2 (en) 2000-09-25 2001-09-25 Live influenza vaccine and method of manufacture

Publications (1)

Publication Number Publication Date
ATE434035T1 true ATE434035T1 (de) 2009-07-15

Family

ID=8169944

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01985267T ATE434035T1 (de) 2000-09-25 2001-09-25 Lebender influenza impfstoff und verfahren zu seiner herstellung

Country Status (12)

Country Link
US (1) US7494659B2 (de)
EP (1) EP1358319B1 (de)
JP (1) JP5063852B2 (de)
KR (2) KR20030061810A (de)
CN (1) CN1582333B (de)
AT (1) ATE434035T1 (de)
AU (2) AU2002223560B2 (de)
CA (1) CA2423038C (de)
DE (1) DE60139026D1 (de)
DK (1) DK1358319T3 (de)
ES (1) ES2327103T3 (de)
WO (1) WO2002024876A2 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
JP4837827B2 (ja) 1998-06-12 2011-12-14 マウント シナイ スクール オブ メディシン 新規なウイルス増殖方法およびそのためのインターフェロン欠損培養基
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
WO2001077394A1 (en) 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US20030027135A1 (en) 2001-03-02 2003-02-06 Ecker David J. Method for rapid detection and identification of bioagents
US20040121309A1 (en) 2002-12-06 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues
US7666588B2 (en) 2001-03-02 2010-02-23 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US7226739B2 (en) 2001-03-02 2007-06-05 Isis Pharmaceuticals, Inc Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
WO2004060278A2 (en) 2002-12-06 2004-07-22 Isis Pharmaceuticals, Inc. Methods for rapid identification of pathogens in humans and animals
US7718354B2 (en) 2001-03-02 2010-05-18 Ibis Biosciences, Inc. Methods for rapid identification of pathogens in humans and animals
US7217510B2 (en) 2001-06-26 2007-05-15 Isis Pharmaceuticals, Inc. Methods for providing bacterial bioagent characterizing information
US8073627B2 (en) 2001-06-26 2011-12-06 Ibis Biosciences, Inc. System for indentification of pathogens
WO2003060088A2 (en) * 2002-01-15 2003-07-24 Acambis, Inc. Viral vaccine production method
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
EP1499348B1 (de) 2002-04-26 2014-10-01 MedImmune, LLC Verfahren zur erzeugung von infectiösen grippevirus b in zellkultur
CA2491992A1 (en) 2002-07-09 2004-01-15 Baxter International, Inc. Animal protein free media for cultivation of cells
AU2003264144C1 (en) 2002-09-05 2009-12-17 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
US7262045B2 (en) 2003-02-25 2007-08-28 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
US8046171B2 (en) 2003-04-18 2011-10-25 Ibis Biosciences, Inc. Methods and apparatus for genetic evaluation
US8057993B2 (en) 2003-04-26 2011-11-15 Ibis Biosciences, Inc. Methods for identification of coronaviruses
US8158354B2 (en) 2003-05-13 2012-04-17 Ibis Biosciences, Inc. Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US7964343B2 (en) 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
WO2005018539A2 (en) * 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
ATE478137T1 (de) 2003-06-20 2010-09-15 Microbix Biosystems Inc Verbesserungen bei der virusproduktion
US8242254B2 (en) 2003-09-11 2012-08-14 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8163895B2 (en) 2003-12-05 2012-04-24 Ibis Biosciences, Inc. Compositions for use in identification of orthopoxviruses
AU2004308328B2 (en) 2003-12-23 2009-06-04 Medimmune, Llc Multi plasmid system for the production of influenza virus
US7666592B2 (en) 2004-02-18 2010-02-23 Ibis Biosciences, Inc. Methods for concurrent identification and quantification of an unknown bioagent
US8119336B2 (en) 2004-03-03 2012-02-21 Ibis Biosciences, Inc. Compositions for use in identification of alphaviruses
US20060024670A1 (en) 2004-05-18 2006-02-02 Luke Catherine J Influenza virus vaccine composition and methods of use
ES2641832T3 (es) 2004-05-24 2017-11-14 Ibis Biosciences, Inc. Espectrometría de masas con filtración de iones selectiva por establecimiento de umbrales digitales
US20050266411A1 (en) 2004-05-25 2005-12-01 Hofstadler Steven A Methods for rapid forensic analysis of mitochondrial DNA
EP2902484A1 (de) 2004-05-25 2015-08-05 MedImmune, LLC Influenza-Hämagglutinin- und Neuraminidase-Varianten
BR122015032743B1 (pt) 2004-06-01 2018-04-03 Mount Sinai School Of Medicine Of New York University Vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, seus usos e métodos para produzir uma vacina
AU2005287395A1 (en) * 2004-07-02 2006-03-30 Henry L. Niman Copy choice recombination and uses thereof
US7811753B2 (en) 2004-07-14 2010-10-12 Ibis Biosciences, Inc. Methods for repairing degraded DNA
AU2011221414B2 (en) * 2004-10-29 2012-09-20 Takeda Pharmaceutical Company Limited Animal Protein-Free Media for Cultivation of Cells
US20060094104A1 (en) * 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
EP1855713B1 (de) * 2005-02-15 2016-04-27 Mount Sinai School of Medicine Gentechnisch hergestellter pferde-influenza-virus und seine verwendungen
US8084207B2 (en) 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
US20060205040A1 (en) 2005-03-03 2006-09-14 Rangarajan Sampath Compositions for use in identification of adventitious viruses
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
BRPI0613287A2 (pt) 2005-06-17 2010-12-28 Sanofi Pasteur cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna
WO2006134433A1 (en) * 2005-06-17 2006-12-21 Sanofi Pasteur Dengue serotype 1 attenuated strain
EP1904655A2 (de) 2005-07-21 2008-04-02 Isis Pharmaceuticals, Inc. Verfahren zur raschen identifizierung und quantifizierung von nukleinsäurevarianten
US20070111309A1 (en) * 2005-10-04 2007-05-17 Daelli Marcelo G Vero cell line adapted to grow in suspension
EP1957521B1 (de) * 2005-10-17 2014-02-19 Ibis Biosciences, Inc. Zusammensetzungen zur verwendung bei der identifikation von influenza-viren
SI2522717T1 (sl) 2006-01-04 2014-05-30 Baxter International Inc. Mediji celične kulture brez oligopeptidov
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
GB0605247D0 (en) * 2006-03-15 2006-04-26 Chiron Srl Compositions and methods for immunisation
MX2008014391A (es) * 2006-05-12 2009-03-06 Bharat Biotech Int Ltd Una composicion util como vacuna.
EP2049662A4 (de) * 2006-07-21 2009-12-30 Medimmune Llc Verfahren und zusammensetzungen zur erhöhung des replikationsvermögens eines influenza-virus
JP2010500034A (ja) * 2006-08-09 2010-01-07 メッドイミューン バクシーンズ，インコーポレイティド インフルエンザ赤血球凝集素変異体およびノイラミニダーゼ変異体
AU2007353877B2 (en) 2006-09-14 2012-07-19 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
EP1911836A1 (de) * 2006-10-12 2008-04-16 AVIR Green Hills Biotechnology Trading GmbH Mediumzusatz für die Virusproduktion
JP5680304B2 (ja) 2007-02-23 2015-03-04 アイビス バイオサイエンシズ インコーポレイティッド 迅速な法医学的ｄｎａ分析法
US9598724B2 (en) 2007-06-01 2017-03-21 Ibis Biosciences, Inc. Methods and compositions for multiple displacement amplification of nucleic acids
EP2674486A1 (de) 2007-06-18 2013-12-18 MedImmune, LLC Influenza-B-Viren mit Veränderungen im Hämagglutininpolypeptid
US8198256B2 (en) * 2007-07-03 2012-06-12 Kyorin Pharmaceutical Co., Ltd. Treatment of influenza
US8084594B2 (en) * 2007-07-13 2011-12-27 The United States Of America As Represented By The Secretary Of Agriculture H2N3 influenza A viruses and methods of use
RU2523587C2 (ru) * 2008-07-11 2014-07-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейрамидазы вируса гриппа
US8534447B2 (en) 2008-09-16 2013-09-17 Ibis Biosciences, Inc. Microplate handling systems and related computer program products and methods
EP2349549B1 (de) 2008-09-16 2012-07-18 Ibis Biosciences, Inc. Mischpatronen, mischstationen und verwandte ausrüstungen, und system
WO2010033627A2 (en) 2008-09-16 2010-03-25 Ibis Biosciences, Inc. Sample processing units, systems, and related methods
US9233148B2 (en) * 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
EP2396803A4 (de) 2009-02-12 2016-10-26 Ibis Biosciences Inc Ionisationssondenanordnungen
EP2396033B1 (de) 2009-02-12 2016-09-28 MedImmune, LLC Influenza-hämagglutinin- und neuraminidase-varianten
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
CN102482666B (zh) 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
CA2709340A1 (en) * 2009-07-10 2011-01-10 University Of Ottawa Mutations in the influenza a virus ns1 gene and use thereof
EP2454000A4 (de) 2009-07-17 2016-08-10 Ibis Biosciences Inc Systeme zur identifizierung von biowirkstoffen
US8950604B2 (en) 2009-07-17 2015-02-10 Ibis Biosciences, Inc. Lift and mount apparatus
EP2957641B1 (de) 2009-10-15 2017-05-17 Ibis Biosciences, Inc. Multiple-displacement-amplifikation
RU2420314C1 (ru) * 2009-12-02 2011-06-10 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) Способ получения живой культуральной вакцины против вируса гриппа
CN102939104A (zh) * 2010-06-01 2013-02-20 诺华有限公司 用冻干浓缩疫苗抗原
CN103096922B (zh) 2010-07-06 2019-08-06 变异生物技术公司 用于治疗流行性感冒的组合物和方法
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
CN103269716B (zh) 2010-12-02 2015-05-27 昂科利蒂克斯生物科技公司 冻干病毒制剂
US20130323280A1 (en) 2011-01-13 2013-12-05 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
EP2802353A4 (de) 2012-01-12 2015-12-02 Variation Biotechnologies Inc Zusammensetzungen und verfahren zur behandlung von virusinfektionen
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物
CN102660511B (zh) * 2012-05-17 2013-08-21 肇庆大华农生物药品有限公司 一种降低血清中胰酶抑制物的方法及其应用
MX372963B (es) 2013-03-13 2020-04-01 Seqirus Uk Ltd Reordenamiento del virus de influenza b.
CN104056276B (zh) * 2013-03-20 2017-05-10 上海生物制品研究所有限责任公司 一种流感病毒减毒活疫苗及其制备方法
CN111500631B (zh) 2013-10-28 2024-03-29 蓝天免疫疗法有限责任公司 用于病毒疗法的新型流感病毒载体
MA41506A (fr) * 2015-02-13 2017-12-19 Takeda Vaccines Inc Procédés de production de virus pour produire des vaccins
EP3261664A1 (de) 2015-02-26 2018-01-03 Boehringer Ingelheim Vetmedica GmbH Bivalenter schweineinfluenzavirusimpfstoff
US11268071B2 (en) 2017-03-30 2022-03-08 Merck Sharp And Dohme Corp. Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids
EP3708658A4 (de) * 2017-11-09 2021-07-28 Jianshun Biosciences Co., Ltd. Verfahren zur akklimatisierung und suspendierung von vero und herstellungsverfahren der zweiten ordnung für virus
WO2019133727A1 (en) 2017-12-29 2019-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Universal influenza virus probe set for enrichment of any influenza virus nucleic acid
CN112143693B (zh) * 2019-06-28 2024-12-27 杭州康万达医药科技有限公司 一种生产病毒的方法及收获液组合物
EP4110381A1 (de) 2020-02-27 2023-01-04 Takeda Vaccines, Inc. Verfahren zur entfernung von wirtszellen-dna aus einer viruspräparation
CN117330750A (zh) * 2023-12-01 2024-01-02 北京生物制品研究所有限责任公司 一种筛选新冠病毒早期毒种的方法和制造疫苗的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
JP4837827B2 (ja) * 1998-06-12 2011-12-14 マウント シナイ スクール オブ メディシン 新規なウイルス増殖方法およびそのためのインターフェロン欠損培養基
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung

Also Published As

Publication number Publication date
US7494659B2 (en) 2009-02-24
ES2327103T3 (es) 2009-10-26
WO2002024876A3 (en) 2003-08-28
DE60139026D1 (de) 2009-07-30
KR20080043891A (ko) 2008-05-19
CA2423038C (en) 2012-03-13
CN1582333B (zh) 2010-06-16
CA2423038A1 (en) 2002-03-28
CN1582333A (zh) 2005-02-16
WO2002024876A2 (en) 2002-03-28
KR20030061810A (ko) 2003-07-22
DK1358319T3 (da) 2009-10-05
AU2002223560B2 (en) 2006-06-29
EP1358319B1 (de) 2009-06-17
AU2356002A (en) 2002-04-02
KR100927517B1 (ko) 2009-11-17
JP2004509903A (ja) 2004-04-02
JP5063852B2 (ja) 2012-10-31
EP1358319A2 (de) 2003-11-05
US20040137013A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
DE60139026D1 (de) Lebender influenza impfstoff und verfahren zu seiner herstellung
EA200801221A1 (ru) Вирусные вакцины, полученные из клеток, с низкими уровнями остаточной клеточной днк
ATE429246T1 (de) Verfahren zur herstellung von biologischen produkten in protein-freiem kultur
BRPI0518568A2 (pt) mÉtodo para produzir uma partÍcula do vÍrus da influenza replicativo sem o uso de vÍrus auxiliar, partÍcula de vÍrus da influenza replicativo, cÉlula, composiÇço, uso de uma composiÇço, mÉtodo para gerar proteÇço imunolàgica contra infecÇço de um indivÍduo com um vÍrus da influenza, e, Ácido nuclÉico
EA200900784A1 (ru) Вакцины, включающие антиген из четырех штаммов вируса гриппа
EA200501890A1 (ru) Вирусы гриппа высокого титра для приготовления вакцин и генной терапии
DK1216053T3 (da) Influenzavaccine
ATE286537T1 (de) Vakzinproduktion
EP1504112A4 (de) Entwicklung einer vakzine zur prävention von infektionen mit dem filovirus bei primaten
AR011216A1 (es) Una vacuna a base de antigenos superficiales contra la gripe, un metodo para prepararla y un metodo para la preparacion de proteinas antigenicas superficiales a partir de virus de gripe propagados sobre un cultivo celular animal
ATE469972T1 (de) Multiplasmid-system zur erzeugung des grippevirus
ATE46920T1 (de) Viren und impfstoffe.
ATE257175T1 (de) Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
ATE306252T1 (de) Verfahren zur herstellung kristalliner partikel zur inhalation
IL147447A0 (en) Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines
MY128999A (en) Purification of hbv antigens for use in vaccines
DE60311990D1 (de) Verfahren zur herstellung eines virus inaktivierten thrombin präparates
MXPA01013302A (es) Vacunas para el virus de la parainfluenza (piv) quimerico para humanos-bovinos atenuadas.
ATE427119T1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
NO20020615D0 (no) Vaksine
ATE494377T1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden
DK1802746T3 (da) Virosompartikler indeholdende antigener fra influenzavirus og hepatitis B-virus
JP6708636B2 (ja) Ｂｓｔ２遺伝子の機能が喪失された細胞株を利用したウィルス感染促進及び産生増進方法
PE20212213A1 (es) Cepas de vbi y usos de las mismas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1358319

Country of ref document: EP